Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: ESAIY )

7.150 -0.028 (-0.39%)
Streaming Delayed Price Updated: 3:58 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 135,986
Open 7.140
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 7.178
Today's Range 7.120 - 7.160
52wk Range 6.500 - 12.24
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Investors Might Hammer Biogen Despite Its Earnings Beat
Biogen beat Q4 views Wednesday, but guided lower on 2025 profit. 
Via Investor's Business Daily
Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study
Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment. 
Via Benzinga

Performance

YTD
+5.77%
+5.77%
1 Month
-2.19%
-2.19%
3 Month
-0.97%
-0.97%
6 Month
-30.65%
-30.65%
1 Year
-34.52%
-34.52%

More News

Read More
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
Via Talk Markets
Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
Via Benzinga
Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED
Via Talk Markets
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
Via Investor's Business Daily
The 3 Best Neuroscience Biotech Stocks to Buy Now
Via InvestorPlace
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
Via Talk Markets
3 Highly Rated Biotech Stocks for Your July Buy List
Via InvestorPlace
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
Via Benzinga
Exposures Product Safety
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
Via Investor's Business Daily
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
Via Benzinga
Exposures Product Safety
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
Via Investor's Business Daily
Exposures Product Safety
Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
Via Investor's Business Daily
Exposures Product Safety
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
Via Investor's Business Daily
Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
Via Investor's Business Daily
Topics Earnings
Exposures Financial
3 Stocks Wall Street Is Ignoring (But You Shouldn’t): April Edition
Via InvestorPlace
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
Via Investor's Business Daily
Exposures Product Safety
3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good
Via InvestorPlace
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
Via Talk Markets
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
Via InvestorPlace
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Via Investor's Business Daily
3 Aging Population Stocks to Profit from the Boomer Generation
Via InvestorPlace
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.